NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,802.40₹0.00 (0.0%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.96% below the high.
Loading market information…
NSE · APLLTD.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 08:10 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Alembic Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 20.1% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Alembic Pharmaceuticals Limited’s forward annual dividend is ₹12.00 per share, paid annual. The forward yield is 1.5% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Alembic Pharmaceuticals Limited’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of ₹11.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Alembic Pharmaceuticals Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Alembic Pharmaceuticals Limited is a pharmaceutical firm that develops, manufactures, and markets medicinal products both domestically in India and across international markets. Its offerings encompass active pharmaceutical ingredients (APIs) and a wide array of formulations. The company provides both proprietary (branded) and generic medications, addressing numerous therapeutic needs such as cardiovascular health, women's health, gastrointestinal issues, eye and skin conditions, kidney/urinary tract disorders, orthopedic ailments, anti-infective treatments, remedies for cold and cough, and anti-diabetic management. Furthermore, the company engages in the export of its diverse product portfolio. Founded in 1907, Alembic Pharmaceuticals Limited maintains its main office in Vadodara, India.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 | May 6, 2025 | ₹8.00-22.71% vs estimate | ₹17.70B+7.26% vs estimate |
|---|
| Q3 2025 | Feb 3, 2025 | ₹7.00-25.53% vs estimate | ₹16.93B-2.45% vs estimate |
|---|
| Q2 2025 | Nov 7, 2024 | ₹7.14-15.0% vs estimate | ₹16.60B-2.81% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,802.40₹0.00 (0.0%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.96% below the high.
₹4,626.30₹0.00 (0.0%)
Torrent Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 11.82% below the high.
₹1,355.70₹0.00 (0.0%)
Dr. Reddy's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 4.18% below the high.
₹1,678.80₹0.00 (0.0%)
Aurobindo Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 3.56% below the high.
₹1,929.00₹0.00 (0.0%)
Ipca Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 5.35% below the high.
₹842.05₹0.00 (0.0%)
Granules India Limited’s quoted price sits in the upper half of its reported 52-week range, 8.83% below the high.
₹783.95₹0.00 (0.0%)
NATCO Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 36.12% below the high.
